ptr-9 Antibody
Description
Anti-HLA-C Autoantibodies in PTR
Anti-HLA-C autoantibodies have emerged as significant contributors to primary and persistent PTR (P/P PTR). A 2024 study analyzed 114 hematologic patients and found:
| Parameter | P/P PTR Incidence | Anti-HLA-C Autoantibody Prevalence |
|---|---|---|
| Results | 63.63% (21/33 PTR cases) | 10.71% (6/56 HLA-I-positive patients) |
-
Anti-HLA-C autoantibodies were identified as independent risk factors for P/P PTR (OR = 3.171, p = 0.028), correlating with poor transfusion efficacy .
-
Patients with anti-HLA-C autoantibodies showed 22.80% efficacy in ABO/D-matched transfusions vs. 36.97% in general PTR cases .
Anti-CD36 Antibodies
Anti-CD36 antibodies are linked to immune-mediated thrombocytopenia and PTR. A 2022 study developed monoclonal antibodies (e.g., GZ-608, GZ-70) to improve detection:
| Serum Sample | Diagnosis | Optical Density (mAb GZ-608) |
|---|---|---|
| 6 | T-lymphoblastic tumor | 3.143 |
| 11 | Alcoholic cirrhosis | 0.384 |
| 14 | Myelodysplastic syndrome | 0.143 |
-
Elevated CD36 antibody levels were observed in patients with malignancies and fetal/neonatal alloimmune thrombocytopenia (FNAIT) .
HLA Class I Antibodies
HLA class I antibodies (anti-HLA-A, -B, -C) are primary drivers of PTR:
| Antibody Type | Prevalence in PTR Patients | Transfusion Efficacy |
|---|---|---|
| Anti-HLA-I | 49.12% (56/114 patients) | 36.97% (ABO/D-matched) |
| Anti-HLA-II | 36.84% (42/114 patients) | – |
-
HLA antibody-positive patients required gene-matched transfusions to improve efficacy (5/6 cases successful) .
Novel Mechanisms: Surface TLR9 (sTLR9) in Immune Regulation
While not directly linked to PTR, surface TLR9 (sTLR9) on neutrophils and B cells modulates immune responses:
-
sTLR9 on neutrophils can initiate CpG DNA-mediated signaling independently of endosomal TLR9, influencing inflammatory responses .
-
In B cells, sTLR9 interacts with mitochondrial DNA (mtDNA) to regulate systemic inflammation .
Therapeutic Strategies for Antibody-Mediated PTR
Key Challenges in PTR Management
-
Antibody Diversity: HLA-C autoantibodies, CD36 antibodies, and HPA antibodies complicate universal solutions .
-
Resource Limitations: HLA-matched platelets are scarce, and cross-matching protocols are labor-intensive .
Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
